Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s pharmaceutical sales during the first half of 2025.Keytruda, approved for several types of cancers, has played an instrumental role in driving...
